- The Supreme Court won't take up drugmakers' IRA casesThe Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca…Endpoints · 2mo ago↗ source
- Regeneron immunotherapy combo comes up short in melanoma trial<p>A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out bi…BioPharma Dive · 2mo ago↗ source
- Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent cli…